Daratumumab
- Generic Name
- Daratumumab
- Brand Names
- Darzalex, Darzalex Faspro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 945721-28-8
- Unique Ingredient Identifier
- 4Z63YK6E0E
- Background
Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind.
...
- Indication
Daratumumab is indicated as an intravenous injection alone or in combination with other medications for the treatment of multiple myeloma. It is available as a combination product with hyaluronidase for the treatment of adults with multiple myeloma as monotherapy or combination therapy and light chain amyloidosis in combination with other drugs.
- Associated Conditions
- Multiple Myeloma (MM), Primary Amyloidosis, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
- Associated Therapies
- -
MUK Nine b: OPTIMUM Treatment Protocol
- Conditions
- Interventions
- First Posted Date
- 2017-06-15
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- University of Leeds
- Target Recruit Count
- 95
- Registration Number
- NCT03188172
- Locations
- 🇬🇧
Bristol Haematology & Oncology Centre, Bristol, United Kingdom
🇬🇧Queen Elizabeth Hospital, Birmingham, United Kingdom
🇬🇧Birmingham Heartlands Hospital, Birmingham, United Kingdom
A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 13
- Registration Number
- NCT03187262
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University of Washington, Seattle, Washington, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide and a Proteasome InhibitorDaratumumab/Pomalidomide/Dexamethasone vs Pomalidomide/Dexamethasone
- Conditions
- Interventions
- First Posted Date
- 2017-06-08
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 304
- Registration Number
- NCT03180736
- Locations
- 🇮🇹
Ancona, Ancona, Italy
🇮🇹Brescia, Brescia, Italy
🇨🇿Praha 2, Praha, Czechia
Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.
- Conditions
- Interventions
- First Posted Date
- 2017-05-18
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 466
- Registration Number
- NCT03158688
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Baylor Charles A Sammons Cancer Center at Dallas, Dallas, Texas, United States
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Daratumumab in Treatment of PGNMID and C3 GN
- First Posted Date
- 2017-03-29
- Last Posted Date
- 2022-08-31
- Lead Sponsor
- Fernando Fervenza
- Target Recruit Count
- 12
- Registration Number
- NCT03095118
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Neoadjuvant Listeria or Daratumumab in Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-01-30
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT03035357
A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-01-18
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 100
- Registration Number
- NCT03023423
Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
- Conditions
- Interventions
- First Posted Date
- 2017-01-05
- Last Posted Date
- 2022-12-30
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 34
- Registration Number
- NCT03011034
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇷🇺City Clinical Hospital # 40, Moscow, Russian Federation
🇮🇹Azienda Ospedaliero Universitaria Careggi, Firenze, Italy
2015-12: a Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- First Posted Date
- 2016-12-28
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 50
- Registration Number
- NCT03004287
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
- First Posted Date
- 2016-12-22
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- Celgene
- Target Recruit Count
- 18
- Registration Number
- NCT03000452
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.